Drug-Induced Vanishing Bile Duct Syndrome: From Pathogenesis to Diagnosis and Therapeutics
Overview
Affiliations
The most concerned issue in the context of drug/herb-induced chronic cholestasis is vanishing bile duct syndrome. The progressive destruction of intrahepatic bile ducts leading to ductopenia is usually not dose dependent, and has a delayed onset that should be suspected when abnormal serum cholestasis enzyme levels persist despite drug withdrawal. Immune-mediated cholangiocyte injury, direct cholangiocyte damage by drugs or their metabolites once in bile, and sustained exposure to toxic bile salts when biliary epithelium protective defenses are impaired are the main mechanisms of cholangiolar damage. Current therapeutic alternatives are scarce and have not shown consistent beneficial effects so far. This review will summarize the current literature on the main diagnostic tools of ductopenia and its histological features, and the differential diagnostic with other ductopenic diseases. In addition, pathomechanisms will be addressed, as well as the connection between them and the supportive and curative strategies for ductopenia management.
Bessone F, Hillotte G, Tamagnone N, Arnedillo D, Roma M J Clin Transl Hepatol. 2025; 13(2):162-168.
PMID: 39917470 PMC: 11797819. DOI: 10.14218/JCTH.2024.00325.
Yu H, Lv T, Li S, Chen S, Li M, Liu J Am J Surg Pathol. 2024; 49(3):265-272.
PMID: 39704223 PMC: 11834957. DOI: 10.1097/PAS.0000000000002343.
Glucocorticoid efficacy and treatment strategies for drug-induced liver injury: a literature review.
Wang P, Guo G, Jiang S, Ding D, Yang J, Lu Y Mol Biol Rep. 2024; 51(1):879.
PMID: 39083110 DOI: 10.1007/s11033-024-09806-w.
Cholangiocyte organoids to study drug-induced injury.
Wang Z, Xing C, van der Laan L, Verstegen M, Spee B, Masereeuw R Stem Cell Res Ther. 2024; 15(1):78.
PMID: 38475870 PMC: 10935784. DOI: 10.1186/s13287-024-03692-6.
Wang J, Wang S, Wu C, Deng Z Infection. 2023; 52(3):891-899.
PMID: 37996645 DOI: 10.1007/s15010-023-02132-6.